A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies.
A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies.
复制标题
DOI：
10.18632/oncotarget.4096
复制
发表时间：
2015-08-28
期刊：
影响因子：
--
通讯作者：
Croce CM
中科院分区：
文献类型：
--
作者：
Drusco A;Bottoni A;Laganà A;Acunzo M;Fassan M;Cascione L;Antenucci A;Kumchala P;Vicentini C;Gardiman MP;Alder H;Carosi MA;Ammirati M;Gherardi S;Luscrì M;Carapella C;Zanesi N;Croce CM
中枢神经系统恶性肿瘤通常需要立体定向活检或活检进行鉴别诊断，以及肿瘤分期和分级。此外，立体定向活检可能是非诊断性的或低估分级。因此，迫切需要新的诊断生物标志物来避免这种侵入性程序。目前已提出了多种生物学标记物，但它们只能识别中枢神经系统肿瘤的特定预后亚型，尚未找到标准化的临床应用。该研究的目的是确定一种可以区分中枢神经系统恶性肿瘤的脑脊液microRNA特征。通过NanoString处理34名肿瘤患者和14名非疾病患者的CSF总RNA。各组（正常、良性、胶质母细胞瘤、髓母细胞瘤、转移瘤和淋巴瘤）之间的比较导致鉴定了microRNA谱，其通过RT-PCR和原位杂交进一步证实。Hsa-miR-451、-711、935、-223和-125b在上述各组中的表达差异显著，这使我们能够绘制一个假设的中枢神经系统恶性肿瘤诊断图。这是第一项使用NanoString技术进行脑脊液microRNA分析的研究。在这篇文章中，我们证明了脑脊液microRNA分析反映了中枢神经系统的生理或病理状况。虽然需要测试更多的病例，但我们确定了一种诊断性脑脊液microRNA特征，对未来的诊断临床应用具有良好的前景。
Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application. The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies. CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization. Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies. This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.